Evidence map›Paper›PMID 15130087›Full record

ArticleThe Biochemical journal2004

MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17.

Amantha Thathiah, Daniel D Carson

Open access · greenAbstract read
In one paragraph

Article in The Biochemical journal, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 1 synthesis or guideline pooled it, 174 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Expression and distribution of MUC1 in the developing and adult kidney.American journal of physiology. Renal physiology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. iScience · 2024
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Emergence ofCancers · 2022
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Amantha ThathiahDepartment of Biological Sciences, University of Delaware, Newark, DE 19716, U.S.A.
Daniel D Carson
University of Delaware · US

Funding

GLYCOPROTEIN MARKERS OF UTERINE RECEPTIVITYR01HD029963 · NICHD · UNIVERSITY OF DELAWARE · PI CARSON, DANIEL D. · 1999 to 2010
$2.1M
GLYCOPROTEIN MARKERS OF UTERINE RECEPTIVITYU01HD029963 · NICHD · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI CARSON, DANIEL D. · 1993 to 2005
$810k
NICHD NIH HHS HD 29963NICHD NIH HHS R01 HD029963NICHD NIH HHS U01 HD029963
6 · The paper itself

Abstract

MUC1, a transmembrane mucin, plays a critical role in embryo implantation, protection of mucosal epithelia from microbial and enzymic attack and various aspects of tumour progression. In some species, a decrease in uterine epithelial MUC1 protein and mRNA expression accompanies embryo implantation. In other species, such as rabbits and humans, MUC1 appears to be locally removed at blastocyst attachment sites, suggesting the action of a protease. We previously demonstrated that MUC1 is proteolytically released from the surface of a human uterine epithelial cell line, HES, and identified TACE/ADAM17 (where TACE stands for tumour necrosis factor-alpha converting enzyme and ADAM for A Disintegrin And Metalloprotease-like) as a constitutive and PMA-stimulated MUC1 sheddase [Thathiah, Blobel and Carson (2003) J. Biol. Chem. 274, 3386-3394]. Further characterization of the proteolytic activity(ies) mediating MUC1 release indicates that MUC1 shedding is also accelerated by the tyrosine phosphatase inhibitor pervanadate. Pervanadate, but not PMA, stimulates MUC1 shedding in TACE-deficient cells, indicating activation of a metalloproteolytic activity(ies) distinct from TACE. Pervanadate-stimulated MUC1 release is inhibited by the TIMP-2 (tissue inhibitor of metalloprotease-2) and TIMP-3, but is unaffected by TIMP-1, consistent with the MT-MMPs (membrane-type matrix metalloproteases). Pervanadate stimulation of MUC1 shedding is absent from MUC1-transfected MT1-MMP-deficient fibroblasts, but is restored after MUC1 and MT1-MMP co-transfection. Furthermore, overexpression of MT1-MMP in HES cells enhances pervanadate-stimulated MUC1 release, and MT1-MMP co-localizes with MUC1 in vivo at the apical surface of receptive-phase human uterine epithelia. Taken together, these studies characterize a MUC1 sheddase activity in addition to TACE and identify MT1-MMP as a pervanadate-stimulated MUC1 sheddase.

Indexed as

ADAM17 ProteinADAM ProteinsCell LineEndometriumEnzyme InhibitorsEpithelial CellsFemaleHumansHydrolysisLuteal PhaseMatrix Metalloproteinases, Membrane-AssociatedMetalloendopeptidasesMucin-1Tumor Necrosis Factor-alphaUterusVanadatesADAM17 ProteinADAM17 protein, humanADAM ProteinsEnzyme InhibitorsMatrix Metalloproteinases, Membrane-AssociatedMetalloendopeptidasesMucin-1pervanadateTumor Necrosis Factor-alphaVanadates

Identifiers

PMID15130087
PMCPMC1133949
OpenAlexW2047317128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.